These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27916408)

  • 1. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
    Frenck RW; Creech CB; Sheldon EA; Seiden DJ; Kankam MK; Baber J; Zito E; Hubler R; Eiden J; Severs JM; Sebastian S; Nanra J; Jansen KU; Gruber WC; Anderson AS; Girgenti D
    Vaccine; 2017 Jan; 35(2):375-384. PubMed ID: 27916408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
    Creech CB; Frenck RW; Sheldon EA; Seiden DJ; Kankam MK; Zito ET; Girgenti D; Severs JM; Immermann FW; McNeil LK; Cooper D; Jansen KU; Gruber W; Eiden J; Anderson AS; Baber J
    Vaccine; 2017 Jan; 35(2):385-394. PubMed ID: 27866765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
    Begier E; Seiden DJ; Patton M; Zito E; Severs J; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Vaccine; 2017 Feb; 35(8):1132-1139. PubMed ID: 28143674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
    Nissen M; Marshall H; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber W; Jansen KU; Emini EA; Anderson AS; Zito ET; Girgenti D
    Vaccine; 2015 Apr; 33(15):1846-54. PubMed ID: 25707693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of a novel 4-antigen
    Inoue M; Yonemura T; Baber J; Shoji Y; Aizawa M; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Hum Vaccin Immunother; 2018; 14(11):2682-2691. PubMed ID: 30084709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.
    Fattom A; Matalon A; Buerkert J; Taylor K; Damaso S; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):632-41. PubMed ID: 25483694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel
    Creech CB; Frenck RW; Fiquet A; Feldman R; Kankam MK; Pathirana S; Baber J; Radley D; Cooper D; Eiden J; Gruber WC; Jansen KU; Anderson AS; Gurtman A
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz532. PubMed ID: 31993453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.
    Xu X; Zhu H; Lv H
    Hum Vaccin Immunother; 2018 Feb; 14(2):314-321. PubMed ID: 29064736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
    Levy J; Licini L; Haelterman E; Moris P; Lestrate P; Damaso S; Van Belle P; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):620-31. PubMed ID: 25715157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine.
    Marshall HS; Baber J; Richmond P; Nissen M; Shakib S; Kreiswirth BN; Zito ET; Severs J; Eiden J; Gruber W; Jansen KU; Jones CH; Anderson AS
    J Infect; 2019 Dec; 79(6):582-592. PubMed ID: 31585191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
    Landrum ML; Lalani T; Niknian M; Maguire JD; Hospenthal DR; Fattom A; Taylor K; Fraser J; Wilkins K; Ellis MW; Kessler PD; Fahim RE; Tribble DR
    Hum Vaccin Immunother; 2017 Apr; 13(4):791-801. PubMed ID: 28010246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease.
    Rozemeijer W; Fink P; Rojas E; Jones CH; Pavliakova D; Giardina P; Murphy E; Liberator P; Jiang Q; Girgenti D; Peters RP; Savelkoul PH; Jansen KU; Anderson AS; Kluytmans J
    PLoS One; 2015; 10(2):e0116945. PubMed ID: 25719409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A; Fuller S; Propst M; Winston S; Muenz L; He D; Naso R; Horwith G
    Vaccine; 2004 Dec; 23(5):656-63. PubMed ID: 15542186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.
    Marshall H; Nissen M; Richmond P; Shakib S; Jiang Q; Cooper D; Rill D; Baber J; Eiden J; Gruber WC; Jansen KU; Anderson AS; Zito ET; Girgenti D
    J Infect; 2016 Nov; 73(5):437-454. PubMed ID: 27519620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunisation With Immunodominant Linear B Cell Epitopes Vaccine of Manganese Transport Protein C Confers Protection against Staphylococcus aureus Infection.
    Yang HJ; Zhang JY; Wei C; Yang LY; Zuo QF; Zhuang Y; Feng YJ; Srinivas S; Zeng H; Zou QM
    PLoS One; 2016; 11(2):e0149638. PubMed ID: 26895191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.
    Harro C; Betts R; Orenstein W; Kwak EJ; Greenberg HE; Onorato MT; Hartzel J; Lipka J; DiNubile MJ; Kartsonis N
    Clin Vaccine Immunol; 2010 Dec; 17(12):1868-74. PubMed ID: 20943877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Vaccines for
    Dupont CD; Scully IL; Zimnisky RM; Monian B; Rossitto CP; O'Connell EB; Jansen KU; Anderson AS; Love JC
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135219
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.
    Li X; Wang X; Thompson CD; Park S; Park WB; Lee JC
    mBio; 2016 Feb; 7(1):e02232-15. PubMed ID: 26838725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
    Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
    Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.